Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

VHT Guru Trades in

VHT Guru Trades in

Q4 2015

VHT Guru Trades in Q4 2015

Ken Fisher 1,808 sh (New)
» More
Q1 2016

VHT Guru Trades in Q1 2016

Ken Fisher Sold Out
» More

Ratios

vs
industry
vs
history
P/E(ttm) 21.00
VHT's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 21.00 )
Ranked among companies with meaningful P/E(ttm) only.
VHT' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.37
Current: 21
0
24.37
PE(NRI) 21.00
VHT's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 21.00 )
Ranked among companies with meaningful PE(NRI) only.
VHT' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.37
Current: 21
0
24.37
P/B 3.39
VHT's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 3.39 )
Ranked among companies with meaningful P/B only.
VHT' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.95
Current: 3.39
0
3.95

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.42
VHT's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 1.42 )
Ranked among companies with meaningful Dividend Yield only.
VHT' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.87
Current: 1.42
0
1.87
Yield on cost (5-Year) 1.42
VHT's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 1.42 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
VHT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.87
Current: 1.42
0
1.87

More Statistics

Short Percentage of Float0.00%
52-Week Range $114.49 - 138.38
Shares Outstanding (Mil)43,059,773.00
» More Articles for VHT

Headlines

Articles On GuruFocus.com
A Low-Risk, High-Growth Play Among Canadian Banks Dec 05 2016 
Bank of Nova Scotia: Canada’s Most International Bank Reports Solid 2016 Earnings Dec 05 2016 
Amazon Go: An E-Tailer’s Relentless Pursuit of Grocery Success Dec 05 2016 
Weekly CFO Sells Highlights Dec 05 2016 
Leukemia Treatment Achieves Promising Results Dec 05 2016 
The Status of Italian Banks Dec 05 2016 
Closed-End Bond Funds Are Ripe for the Picking Dec 05 2016 
Is Mobileye a Buy? Dec 05 2016 
23 Questions With Brazilian Value Investor Gustavo Saiani Dec 05 2016 
23 Questions With Greek Value Investor Dimitrios Koutsoubos Dec 05 2016 

More From Other Websites
Why Merck’s Immunology Business Matters Now Dec 05 2016
[$$] Gearing Up for Growth in the Trump Era Dec 03 2016
Recent R&D Developments from Merck You Won’t Want to Miss Dec 01 2016
Major Product Developments for Pfizer Dec 01 2016
Allergan’s News: Recent Acquisitions and Divestments Nov 29 2016
The Pfizer-Medivation Deal, Completed in 3Q16 Nov 29 2016
Pfizer’s Valuation Compared to Peers Nov 29 2016
Where Does Eli Lilly’s Valuation Stand Next to Peers? Nov 22 2016
The Positive Performance of the Healthcare Sector Nov 21 2016
Can Trump's Presidency Heal Pharma Stocks? (XLV, VHT) Nov 14 2016
Taking Stock of Trump’s Triumph Nov 10 2016
How To Profit With ETFs Under A President Donald Trump Nov 10 2016
This Contributed to Pfizer’s Growth in 3Q16 Nov 07 2016
Pfizer’s 3Q16 Earnings: Revenue Stream Nov 07 2016
The One Election-Proof Industry Nov 02 2016
Merck & Co.’s Profitability in 3Q16 Nov 01 2016
Obamacare: Will the Next US President Kill It or Cure It? Oct 31 2016
Factors Impacting Merck & Co.’s Growth in 3Q16 Oct 28 2016
Inside Opdivo, Bristol-Myers Squibb’s Oncology Drug Oct 26 2016
Johnson & Johnson’s Valuation Cheat Sheet 3Q16 Oct 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK